Federation des caisses Desjardins du Quebec’s Spero Therapeutics SPRO Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	+91,900	New	+$240K	﹤0.01%	1600
2025 Q1	–	Sell	-30	Closed	-$31	–	2750
2024 Q4	$31	Hold	30	–	–	﹤0.01%	2528
2024 Q3	$40	Hold	30	–	–	﹤0.01%	2526
2024 Q2	$39	Hold	30	–	–	﹤0.01%	2439
2024 Q1	$52	Sell	30 -700	-96%	-$1.1K	﹤0.01%	2363
2023 Q4	$1.07K	Hold	730	–	–	﹤0.01%	2145
2023 Q3	$883	Hold	730	–	–	﹤0.01%	2161
2023 Q2	$1.06K	Buy	730 +30	+4%	+$51	﹤0.01%	2127
2023 Q1	$1.01K	Buy	+700	New	+$1.17K	﹤0.01%	2152

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SPRO Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 91,900 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #1600 among its holdings. This is a return to the name: Federation des caisses Desjardins du Quebec previously reported a position in SPRO as recently as Q4 2024.

Federation des caisses Desjardins du Quebec first reported a position in SPRO in Q1 2023 and has held it in 9 quarters since. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Federation des caisses Desjardins du Quebec held 91,900 shares of Spero Therapeutics worth $202K as of Q2 2026.
Spero Therapeutics was a new Federation des caisses Desjardins du Quebec position in Q2 2026.
Spero Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #1600 holding.
Federation des caisses Desjardins du Quebec first reported a position in Spero Therapeutics in Q1 2023 and has held it in 9 quarters since.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.